Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy
Breast cancer is the most frequent malignant neoplastic disease in women, with an estimated 2.3 million cases in 2020 worldwide. Its treatment depends on characteristics of the patient and the tumor. In the latter, characteristics include cell type and morphology, anatomical location, and immunophen...
Main Authors: | Gabriel Méndez-Valdés, Francisca Gómez-Hevia, Maria Chiara Bragato, José Lillo-Moya, Catalina Rojas-Solé, Luciano Saso, Ramón Rodrigo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Antioxidants |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3921/12/2/457 |
Similar Items
-
Risks of trastuzumab‐related cardiotoxicity in breast cancer patients in Taiwan
by: Wei‐Ting Chang, et al.
Published: (2021-12-01) -
Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
by: Holden Eaton, et al.
Published: (2023-04-01) -
Chemotherapy-induced cardiotoxic effect in breast cancer patients treated with trastuzumab (Herceptin) by MRI
by: Mohamed Aboulfotouh Mourad, et al.
Published: (2023-12-01) -
Early cardiotoxicity after adjuvant concomitant treatment with radiotherapy and trastuzumab in patients with breast cancer
by: Marinko Tanja, et al.
Published: (2018-02-01) -
Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
by: Sarita Shrivastva, et al.
Published: (2023-07-01)